Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality

BACKGROUND: The US Food and Drug Administration authorized COVID-19 convalescent plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadevall, Arturo, Dragotakes, Quigly, Johnson, Patrick W, Senefeld, Jonathon W, Klassen, Stephen A, Wright, R Scott, Joyner, Michael J, Paneth, Nigel, Carter, Rickey E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Epidemiology and Global Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205484/
https://www.ncbi.nlm.nih.gov/pubmed/34085928
http://dx.doi.org/10.7554/eLife.69866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205484/
https://www.ncbi.nlm.nih.gov/pubmed/34085928
http://dx.doi.org/10.7554/eLife.69866

Ejemplares similares